

ANTIDEPRESSANTS**Drug(s) Applied:**

EMSAM; FETZIMA; FETZIMA TITRATION PACK; VENLAFAXINE TABLETS 112.5MG

ST Criteria	Trial of two generics of the following formulary products: bupropion, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine (capsule or solution), fluvoxamine, mirtazapine, paroxetine (tablet or suspension), sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.
--------------------	---

ATYPICAL ANTIPSYCHOTICS**Drug(s) Applied:**

FANAPT; FANAPT TITRATION PACK; LYBALVI; SECUADO; VRAYLAR

ST Criteria	Trial of two of the following oral generic formulary atypical antipsychotic agents: aripiprazole (tablet, ODT or oral solution), asenapine, olanzapine (tablet, ODT or intramuscular injection), paliperidone, quetiapine, risperidone (tablet or ODT), ziprasidone. Approve for continuation of prior therapy.
--------------------	---

GLUCAGON**Drug(s) Applied:**

GLUCAGEN HYPOKIT

ST Criteria	Trial of one of the following: Baqsimi, Gvoke or glucagon.
--------------------	--

INHALED CORTICOSTEROID**Drug(s) Applied:**

QVAR REDIMALER

ST Criteria	Trial of Arnuity Ellipta and either Flovent Diskus or Flovent HFA.
--------------------	--

INVEGA HAFYERA THERAPY**Drug(s) Applied:**

INVEGA HAFYERA

ST Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
--------------------	--

NAMZARIC**Drug(s) Applied:**

NAMZARIC

ST Criteria	Trial of generic memantine extended-release.
--------------------	--

NON-PREFERRED SGLT2S**Drug(s) Applied:**

INVOKAMET; INVOKAMET XR; INVOKANA

ST Criteria	Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes with either diabetic nephropathy or established cardiovascular disease.
--------------------	---

PD AGENTS**Drug(s) Applied:**

NEUPRO

ST Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole.
--------------------	---

RELISTOR**Drug(s) Applied:**

RELISTOR (TABLET, INJECTION)

ST Criteria	Trial of constulose, enulose, Generalac, lactulose or lubiprostone.
--------------------	---

RYTARY**Drug(s) Applied:**

RYTARY

ST Criteria	Trial of one generic carbidopa/levodopa (tablet or ER tablet) containing formulation.
--------------------	---

ACTINIC KERATOSIS**Drug(s) Applied:**

DICLOFENAC 3% GEL; KLISYRI; PICATO

ST Criteria	Trial of either topical fluorouracil or topical imiquimod.
--------------------	--

STATINS**Drug(s) Applied:**

LIVALO

ST Criteria	Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statins): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin.
--------------------	--

GLP1 AGONISTS**Drug(s) Applied:**

MOUNJARO;OZEMPIC;RYBELSUS;SOLIQUA;TRULICITY;VICTOZA

ST Criteria	Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Ozempic (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide): Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.
--------------------	---